RNAi / siRNA vs ASO — Rare Disease Deal Terms Comparison
Market Analysis
In rare disease, RNAi / siRNA and ASO represent two of the most actively transacted modalities. At Phase 2, RNAi / siRNA deals carry a median total deal value of $2.5B with $456M upfront, compared to $2.5B total value and $456M upfront for ASO. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. RNAi / siRNA development milestones average $441M versus $441M for ASO. Commercial milestones are $1.1B for RNAi / siRNA and $1.1B for ASO. Royalty rates range from 8.2%-16.4% for RNAi / siRNA and 8.2%-16.4% for ASO.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do RNAi / siRNA and ASO deal terms compare in rare disease?
Which modality commands higher royalty rates: RNAi / siRNA or ASO?
How do milestone structures differ between RNAi / siRNA and ASO?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.